Background. In patients with hepatocellular carcinoma, selection criteria for transarterial
hepatic selective internal radiotherapy are imprecise. Additionally, radiographic parameters …

PURPOSE: To present the findings of a risk-stratification survival analysis with use of data
collected on a heterogeneous group of patients with hepatocellular carcinoma (HCC) …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has limited treatment options;
long-term outcomes following intra-arterial radiation are unknown. We assessed clinical …

Purpose Selective internal radiation therapy (SIRT) is an effective treatment strategy for
unresectable hepatocellular carcinoma (HCC) patients. However, the prognoses of patients …

Aim: Several techniques for radionuclide therapy of hepatocellular carcinoma (HCC) have
been developed. In this overview the available radionuclide treatment modalities for HCC …

Abstract Yttrium‐90 radioembolization (Y90RE) is a novel approach to radiation therapy for
hepatocellular carcinoma (HCC), never tested in phase 2 studies. Fifty‐two patients with …

Purpose In light of recently published clinical reports and trials, the TheraSphere Global
Dosimetry Steering Committee (DSC) reconvened to review new data and to update …

ABSTRACT Yttrium-90 (90 Y) radioembolization is a catheter-based therapy that delivers
internal radiation to hepatic tumors in the form of microspheres. 90 Y can be delivered to the …

The liver is a common site of metastasis, with essentially all metastatic malignancies having
been known to spread to the liver. Nearly half of all patients with extrahepatic primary cancer …

Administration of yttrium‐90 microspheres via the hepatic artery is an attractive approach to
selectively deliver therapeutic doses of radiation to liver malignancies. This procedure …